Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 385 of 6351
-
Can a gentle brain zapping schedule ease Parkinson's symptoms?
Disease control Recruiting nowThe goal of this clinical trial is to compare the efficacy and safety of different Intervention Intervals of subthalamic nucleus-targeted transcranial temporal interference stimulation (STN-tTIS) in patients with Parkinson disease. Previous studies suggest that STN-tTIS may impr…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets MTAP deletion
Disease control Recruiting nowThis is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer …
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Hope for scleroderma: new pill aims to halt disease progression
Disease control Recruiting nowNerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited …
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Growing heart valve could spare kids multiple surgeries
Disease control Recruiting nowProspective, single-arm, multi-center, continued access study of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects…
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for GIST: velzatinib takes on imatinib in major trial
Disease control Recruiting nowGastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effectiv…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could a common antioxidant shield cancer patients from painful mouth sores?
Symptom relief Recruiting nowColorectal cancer (CRC) represents one of the most common cancers worldwide and 5-Fluorouracil (5-FU) is still the mainstay of treatment. However, 5-FU is often implicated in inducing oral mucositis (OM), a painful inflammatory condition that may hinder oral intake, negatively im…
Phase 2/3 • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Which workout wins for breast cancer recovery? a trial puts cardio vs conditioning to the test
Symptom relief Recruiting nowIn this study, the investigators hypothesize that observed intense resistance training with conditioning elicits similar changes in body composition, muscle mass, and blood pressure as that with cardiovascular training (or cardio) for women treated with breast cancer.
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Can coffee lovers with AF keep their daily cup? a trial investigates
Disease control Recruiting nowThe CAFIB trial is a multicenter, randomized, open-label, crossover clinical trial designed to determine whether habitual caffeine consumption in coffe adversely affects rate control in patients with permanent atrial fibrillation (AF). The rationale stems from the discrepancy be…
Phase 2/3 • Sponsor: Hospital Universitario Getafe • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Which antibiotic combo wins against h. pylori? a Head-to-Head test
Disease control Not yet recruitingThis randomized, open-label clinical trial will compare two bismuth-containing quadruple therapies for the first-line treatment of Helicobacter pylori infection. Adults aged 18 years or older with confirmed H. pylori infection who have not previously received eradication treatmen…
Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for tough lymphoma: drug combo aims to boost transplant success
Disease control Recruiting nowThis phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before autologous stem cell transplant in treating patients with d…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo ablation aims to tame stubborn AFib
Disease control Not yet recruitingThe goal of this clinical trial is to test if a more complete ablation procedure works better than the standard procedure for people with long-lasting persistent atrial fibrillation (AF). AF is a heart rhythm problem that can cause a fast or uneven heartbeat. This study will inc…
Sponsor: Yunlong Wang • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could cannabis calm drug-resistant epilepsy? new trial seeks answers.
Disease control Not yet recruitingEpilepsy is a neurological disorder affecting more than 50 million people globally, including more than 260,000 Canadians. Cannabidiol (CBD) reduces seizure frequency and improves quality of life for adults and children with Drug Resistant Epilepsy (DRE). Several uncontrolled, sm…
Phase 2 • Sponsor: University of Manitoba • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could an immune drug ease schizophrenia symptoms?
Disease control Recruiting nowThe main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.
Phase 2 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new biologic drug prevent COPD Flare-Ups?
Disease control Recruiting nowThe purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.
Phase 2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a daily pill slash high lipoprotein(a) — a hidden heart risk with no approved treatment?
Disease control Not yet recruitingThis is a randomized, double-blind, placebo-controlled Phase II trial evaluating the efficacy and safety of oral SAL0137 in adults with elevated Lp(a) and high cardiovascular risk. Participants will be randomized 1:1:1:1 to receive low-dose SAL0137, medium-dose SAL0137, high-dose…
Phase 2 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug combo aims to tackle myeloma and kidney damage at once
Disease control Recruiting nowThis study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM) accompanied by renal impairment (\[eGFR\] \< 40 mL…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could simple leg exercises restore balance and blood flow after chemotherapy?
Symptom relief Not yet recruitingChemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting side effect of neurotoxic chemotherapy agents, characterized by sensory loss, impaired proprioception, and muscle weakness, predominantly affecting the lower limbs. These impairments significantly contri…
Sponsor: South Valley University • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A Two-Year watch: can brain scans and surveys predict depression and anxiety in teens?
Knowledge-focused Not yet recruitingThis prospective observational cohort study will enroll approximately 200 children and adolescents aged 7-17 years who are at elevated risk for common mental disorders, including depressive disorders, anxiety disorders, and obsessive-compulsive disorder, based on family history o…
Sponsor: Shanghai Mental Health Center • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can a higher dose of an existing eye drug cut injection frequency for wet AMD?
Disease control Not yet recruitingPrimary objective: • To evaluate the change in aqueous humor vascular endothelial growth factor A (VEGF-A) levels after 2 months of initial treatment with 8 mg Aflibercept in treatment-naïve nAMD patients. Secondary objectives: • To assess the efficacy, safety, and biomarker c…
Early phase 1 • Sponsor: Tianjin Medical University Eye Hospital • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Nasal spray aims to tame brain inflammation in ALS
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether a nasal spray medicine called foralumab is safe and easy to tolerate in adults with amyotrophic lateral sclerosis (ALS). ALS is a disease that slowly damages the nerve cells that control movement, causing muscles to grow weaker …
Phase 2 • Sponsor: Tiziana Life Sciences LTD • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC